Last edition
News about "amyloid fibril therapy"
CARES Phase 3 Trial Highlights Anselamimab Potential in Kappa Light Chain Amyloidosis
Anselamimab demonstrated promising efficacy in the phase 3 CARES programme, showing a 62 percent improvement in survival and a 71 percent reduction in cardiovascular hospitalisations among patients with kappa light-chain amyloidosis, despite the study not meeting its primary endpoint in the overall light-chain amyloidosis population.
Amyloid Fibril Therapy | 01/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy